Pleco Therapeutics names Henno Welgemoed as CMO

5 September 2023

Dutch specialty pharma firm Pleco Therapeutics has appointed Dr Henno Welgemoed in the newly created role of chief medical officer (CMO).

Dr Welgemoed will serve on the company’s global leadership team taking on responsibility for the clinical development activities at the company.

Dr Welgemoed is a qualified physician with 15 years of clinical expertise and over two decades of pharmaceutical experience. At Pleco he will lead the implementation of the clinical study for its lead candidate PTX-252, in development for the treatment of acute myeloid leukemia (AML). Pleco said it expects to start the clinical Phase II study for PTX-252 in AML in 2024.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK